or Try an Advanced Search...

    Technical Analysis for LYRA - Lyra Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.39 0.23% 0.00
    LYRA closed down 7.19 percent on Wednesday, May 8, 2024, on 2.5 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 10
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical LYRA trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.23%
    Calm After Storm Range Contraction 0.23%
    NR7 Range Contraction 0.23%
    NR7-2 Range Contraction 0.23%
    Narrow Range Bar Range Contraction 0.23%
    Lower Bollinger Band Walk Weakness 0.23%
    Wide Bands Range Expansion 0.23%
    Below Lower BB Weakness 0.23%
    Down 3 Days in a Row Weakness 0.23%
    Down 4 Days in a Row Weakness 0.23%
    Older End-of-Day Signals for LYRA ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 1 hour ago
    60 Minute Opening Range Breakout about 5 hours ago
    Up 1% about 5 hours ago
    Rose Above Lower Bollinger Band about 6 hours ago
    2x Volume Pace about 6 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    LYRA Chart by TradingView
    Basic chart:

    Profile

    Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions using XTreo technology platform for the localized treatment of patients with ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Sinus Headache Chronic Rhinosinusitis Sinusitis

    Is LYRA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 30 Lyra Therapeutics GAAP EPS of -$0.35 misses by $0.08, revenue of $0.53M beats by $0.18M
    Apr 30 Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates
    Apr 30 Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
    Apr 26 Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Mar 28 Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock?
    Mar 26 Private equity firms who hold 39% of Lyra Therapeutics, Inc. (NASDAQ:LYRA) gained 6.8%, institutions profited as well
    Mar 25 Lyra Therapeutics (LYRA) Is a Great Choice for 'Trend' Investors, Here's Why
    Mar 23 Lyra Therapeutics Inc (LYRA) Posts Year-End Financial Results, Aligns with EPS Projections
    Mar 22 Lyra Therapeutics files for $300M mixed shelf
    Mar 22 Wall Street Analysts See a 101.81% Upside in Lyra Therapeutics (LYRA): Can the Stock Really Move This High?
    See more LYRA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.79
    52 Week Low 0.36
    Average Volume 3,079,167
    200-Day Moving Average 4.30
    50-Day Moving Average 5.21
    20-Day Moving Average 4.40
    10-Day Moving Average 3.50
    Average True Range 0.58
    RSI (14) 12.28
    ADX 23.18
    +DI 10.72
    -DI 56.57
    Chandelier Exit (Long, 3 ATRs) 4.03
    Chandelier Exit (Short, 3 ATRs) 2.10
    Upper Bollinger Bands 7.79
    Lower Bollinger Band 1.01
    Percent B (%b) -0.09
    BandWidth 154.05
    MACD Line -1.04
    MACD Signal Line -0.50
    MACD Histogram -0.5385
    Fundamentals Value
    Market Cap 20.49 Million
    Num Shares 52.6 Million
    EPS -1.40
    Price-to-Earnings (P/E) Ratio -0.28
    Price-to-Sales 178.41
    Price-to-Book 3.04
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.45
    Resistance 3 (R3) 0.45 0.44 0.44
    Resistance 2 (R2) 0.44 0.42 0.43 0.44
    Resistance 1 (R1) 0.41 0.41 0.40 0.41 0.43
    Pivot Point 0.40 0.40 0.39 0.39 0.40
    Support 1 (S1) 0.37 0.38 0.37 0.37 0.35
    Support 2 (S2) 0.36 0.37 0.36 0.34
    Support 3 (S3) 0.33 0.36 0.34
    Support 4 (S4) 0.33